Physician profile
James Chudleigh
NPI 1417963448
$2,190.06
in general payments reported to CMS, 2019-2025
14 companies · $34.31 in 2025
The $34.31 reported for 2025 was less than what a typical Geriatric Medicine (Family Medicine) provider received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,180 · 2020: $113 · 2021: $101 · 2022: $113 · 2023: $616 · 2024: $32.47 · 2025: $34.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $682.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $622.60 | 2019-2023 | Nuplazid |
| Avanir Pharmaceuticals, INC. | $376.77 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $363.47 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $218.86 | 2019 | |
| Sun Pharmaceutical Industries INC. | $169.47 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $134.51 | 2019 | |
| Urovant Sciences INC | $95.47 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $49.55 | 2023 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $35.38 | 2023 | Lokelma |
| Novartis Pharmaceuticals Corporation | $33.17 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $32.47 | 2024 | Dificid |
| Radius Health, INC. | $25.86 | 2023 | |
| Alpha Cognition USA, INC. | $17.38 | 2025 | Zunveyl |
| Lilly USA, LLC | $15.10 | 2023 | Trulicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Chudleigh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.